🇺🇸 Dexamethasone 21-Phosphate in United States

16 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Leukocytosis — 4 reports (25%)
  2. Blast Cells Present — 3 reports (18.75%)
  3. Neutropenia — 2 reports (12.5%)
  4. Blast Cell Count Increased — 1 report (6.25%)
  5. Colitis — 1 report (6.25%)
  6. Enteritis — 1 report (6.25%)
  7. Epistaxis — 1 report (6.25%)
  8. Interstitial Lung Disease — 1 report (6.25%)
  9. Intestinal Perforation — 1 report (6.25%)
  10. Left Ventricular Dysfunction — 1 report (6.25%)

Source database →

Dexamethasone 21-Phosphate in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Dexamethasone 21-Phosphate approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Dexamethasone 21-Phosphate in United States?

Tokat Gaziosmanpasa University is the originator. The local marketing authorisation holder may differ — check the official source linked above.